Health Canada Approves Stelara® to Treat Moderate-to-Severe Psoriasis in Teens

Janssen Inc. announced Health Canada has approved STELARA^® for the treatment of chronic moderate-to-severe plaque psoriasis in adolescent patients (12 to 17 years) who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.²
According to Janssen’s press release:

The Health Canada approval of STELARA^® for adolescents with psoriasis is based on data from the Phase 3 CADMUS study, designed to evaluate the efficacy and safety of STELARA^® in patients aged 12 to 17 years with moderate-to-severe plaque psoriasis. The primary endpoint of the study was the proportion of patients achieving a Physician’s Global Assessment of cleared/minimal (PGA 0/1) at week 12. This psoriasis assessment tool demonstrated that 69.4 per cent of patients who received standard dosing of STELARA^® achieved PGA 0/1 at week 12.⁶

Click here to view the full press release.